Lonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects. It is composed of trifluridine, an antineoplastic nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor. Following uptake into the cancer cells, trifluridine is incorporated into DNA, thereby interfering with DNA synthesis and inhibiting cell proliferation. Tipiracil hydrochloride increases the bioavailability of trifluridine by preventing its rapid metabolism and ensuring the blood concentration of trifluridine is maintained.
TABLE OF CONTENTS
4 Product Profiles
4 Lonsurf : Colorectal cancer (CRC)
LIST OF FIGURES
9 Figure 1: Lonsurf for colorectal cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer
13 Figure 4: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
5 Table 1: Lonsurf drug profile
6 Table 2: Lonsurf Phase III data in colorectal cancer
8 Table 3: Lonsurf Phase II trials in colorectal cancer
14 Table 4: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
16 Table 5: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016–25
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.